Italia markets close in 4 hours 50 minutes

PCAS SA (0NF7.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
12,88-5,43 (-29,64%)
Al 01:29PM BST. Mercato aperto.
Schermo intero
Chiusura precedente18,30
Aperto12,88
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno12,88 - 12,88
Intervallo di 52 settimane12,88 - 12,88
Volume75.000
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,46
Rapporto PE (ttm)N/D
EPS (ttm)-2,95
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    PCAS: NET SALES AS OF MARCH 31, 2022

    Ecully, May 13, 2022 NET SALES AS OF MARCH 31, 2022 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of March 31, 2022. The PCAS Group has generated consolidated net sales of €51.2 million as of March 31, 2022, a 1.2% decrease compared to the same period during the previous financial year (-3.0% at constant exchange rates). In millions of euros 2022

  • GlobeNewswire

    Pcas: Release of the 2021 Universal Registration Document (URD)

    RELEASE OF THE 2021 UNIVERSAL REGISTRATION DOCUMENT (URD) Ecully, April 29, 2022 The PCAS Universal Registration Document 2021, which includes the annual financial report, was filed with France's Financial Markets Authority, in ESEF format (European Single Electronic Format), on April 29, 2022, under number D.22-0386. This document contains: The 2021 annual financial reportThe Board of Directors' corporate governance report in accordance with Section L.225-37 of France's Commercial CodeInformati

  • GlobeNewswire

    PCAS: 2021 ANNUAL RESULTS

    Ecully, February, 24, 2022 2021 ANNUAL RESULTS PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated results as of December 31, 2021. 2020 2021 in millions of euros Net sales 194.1 187.0 EBITDA (*) 10.7 -4.6 EBITDA margin 5.5% -2.5% Current operating income (*) -10.8 -28.2 Current operating income margin -5.5% -15.1% Other operating income and expenses -0.2 -0.4 Opera